Test of the month: The chromogenic antifactor Xa assay

American Journal of Hematology

Volumn 87, Issue 2, 2012, Pages 194-196

  Gehrie, Eric ^a   Laposata, Michael ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; BLOOD CLOTTING FACTOR 10A; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PREKALLIKREIN; RIVAROXABAN; WARFARIN;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; CLINICAL LABORATORY; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; HIP ARTHROPLASTY; HUMAN; INTERNATIONAL NORMALIZED RATIO; KNEE ARTHROPLASTY; OBESITY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; SURGICAL PATIENT;

ANTIBODIES; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CHROMOGENIC COMPOUNDS; DRUG MONITORING; FACTOR XA; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; IMMUNOASSAY; MORPHOLINES; POLYSACCHARIDES; THIOPHENES;

EID: 84855951618     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22222     Document Type: Article

References (17)

1. Janssen Pharmaceuticals Package Insert, Xarelto (Rivaroxaban) Film-Coated Oral Tablets. Titusville, NJ: Janssen Pharmaceuticals; 2010.
2. Arpino PA, Demirjian Z, Van Cott EM. Use of the chromogenic factor X assay to predict the international normalized ratio in patients transitioning from argatroban to warfarin. Pharmacotherapy 2005; 25: 157-164.
3. Long E, Pitfield AF, Kissoon N. Anticoagulation therapy: Indications, monitoring, and complications. Pediatr Emerg Care 2011; 27: 55-64.
4. Hirsh J, Bauer KA, Donati MB, et al. Parenteral Anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 8th ed. Chest 2008; 133: 141S-159S.
5. Clem JR. Anti-factor Xa Levels: When should they be used? S D Med 2006; 59: 261-262.
6. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 188S-203S.
7. Laposata M. Coagulation Disorders: Quality in Laboratory Diagnosis. Demos Medical: New York; 2011. pp 23-42.
8. Michelson AD, Bovill E, Monagle P, Andrew M. Antithrombotic therapy in children. Chest 1998; 114: 748S-769S.
9. Smogorzewska A, Brandt JT, Chandler WL, Cunningham MT, et al. Effect of fondaparinux on coagulation assays: results of College of American Pathologists proficiency testing. Arch Pathol Lab Med 2006; 130: 1605-1611.
10. GlaxoSmithKline (GSK) Package Insert, Arixtra (Fondaparinux Sodium) Injection. Research Triangle Park, NC: GlaxoSmithKline (GSK). 2004.
11. Castellone DD, Van Cott EM. Laboratory monitoring of new anticoagulants. Am J Hematol 2010; 85: 185-187.
12. Toschi V, Lettino M. Inhibitors of propagation of coagulation: Factors V and X. Br J Clin Pharmacol 2011; 72: 563-580.
13. Buller HR, Lensing AWA, Prins MH, et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: The Einstein-DVT dose-ranging study. Blood 2008; 112: 2242-2247.
14. Bates SM, Weitz JI. Coagulation assays. Circulation 2005; 12: e53-e60.
15. Ignjatovic V, Summerhayes R, Gan A, et al. Monitoring unfractionated heparin (UFH) therapy: Which Anti Factor Xa assay is appropriate? Thromb Res 2007; 120: 347-351.
16. Andrew M, Schmidt B. The use of heparin in newborn infants. Semin Thromb Hemost 1988; 14: 28-32.
17. Lindhoff-Last E, Samama MM, Ortel TL, et al. Assays for measuring rivaroxaban: Their suitability and limitations. Drug Monitor 2010; 32: 673-679.